Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

611 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study.
Dimitrakopoulos FI, Mountzios G, Christopoulos P, Papastergiou T, Elshiaty M, Daniello L, Zervas E, Agelaki S, Samantas E, Nikolaidi A, Athanasiadis I, Baka S, Syrigos K, Christopoulou A, Lianos E, Samitas K, Tsoukalas N, Perdikouri EI, Oikonomopoulos G, Kottorou A, Kalofonou F, Makatsoris T, Koutras A, Megalooikonomou V, Kalofonos H. Dimitrakopoulos FI, et al. Among authors: syrigos k. Ther Adv Med Oncol. 2022 Sep 8;14:17588359221122728. doi: 10.1177/17588359221122728. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36105886 Free PMC article.
A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
Kosmas C, Tsavaris N, Syrigos K, Koutras A, Tsakonas G, Makatsoris T, Mylonakis N, Karabelis A, Stathopoulos GP, Kalofonos HP. Kosmas C, et al. Among authors: syrigos k. Cancer Chemother Pharmacol. 2007 Jan;59(1):51-9. doi: 10.1007/s00280-006-0242-5. Epub 2006 Apr 19. Cancer Chemother Pharmacol. 2007. PMID: 16622691 Clinical Trial.
Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group.
Pectasides D, Samantas E, Fountzilas G, Briasoulis E, Kosmidis P, Skarlos D, Dimopoulos MA, Kalofonos HP, Economopoulos T, Syrigos K. Pectasides D, et al. Among authors: syrigos k. Lung Cancer. 2007 Dec;58(3):355-61. doi: 10.1016/j.lungcan.2007.06.027. Epub 2007 Aug 15. Lung Cancer. 2007. PMID: 17698241 Clinical Trial.
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.
Kosmidis PA, Kalofonos HP, Christodoulou C, Syrigos K, Makatsoris T, Skarlos D, Bakogiannis C, Nicolaides C, Bafaloukos D, Bamias A, Samantas E, Xiros N, Boukovinas I, Fountzilas G, Dimopoulos MA. Kosmidis PA, et al. Among authors: syrigos k. Ann Oncol. 2008 Jan;19(1):115-22. doi: 10.1093/annonc/mdm430. Epub 2007 Oct 15. Ann Oncol. 2008. PMID: 17938425 Free article. Clinical Trial.
Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG).
Kosmidis PA, Fountzilas G, Eleftheraki AG, Kalofonos HP, Pentheroudakis G, Skarlos D, Dimopoulos MA, Bafaloukos D, Pectasides D, Samantas E, Boukovinas J, Lambaki S, Katirtzoglou N, Bakogiannis C, Syrigos KN. Kosmidis PA, et al. Among authors: syrigos kn. Ann Oncol. 2011 Apr;22(4):827-834. doi: 10.1093/annonc/mdq445. Epub 2010 Sep 29. Ann Oncol. 2011. PMID: 20880999 Free article. Clinical Trial.
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.
Pectasides D, Papaxoinis G, Kalogeras KT, Eleftheraki AG, Xanthakis I, Makatsoris T, Samantas E, Varthalitis I, Papakostas P, Nikitas N, Papandreou CN, Pentheroudakis G, Timotheadou E, Koutras A, Sgouros J, Bafaloukos D, Klouvas G, Economopoulos T, Syrigos KN, Fountzilas G. Pectasides D, et al. BMC Cancer. 2012 Jun 29;12:271. doi: 10.1186/1471-2407-12-271. BMC Cancer. 2012. PMID: 22748098 Free PMC article. Clinical Trial.
The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab.
Strimpakos A, Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Andreadou A, Sgouros J, Zizi-Sermpetzoglou A, Kominea A, Televantou D, Razis E, Galani E, Pectasides D, Tejpar S, Syrigos K, Fountzilas G. Strimpakos A, et al. Among authors: syrigos k. Clin Colorectal Cancer. 2013 Dec;12(4):267-274.e2. doi: 10.1016/j.clcc.2013.07.001. Epub 2013 Sep 17. Clin Colorectal Cancer. 2013. PMID: 24050852
Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trial.
Pentheroudakis G, Raptou G, Kotoula V, Wirtz RM, Vrettou E, Karavasilis V, Gourgioti G, Gakou C, Syrigos KN, Bournakis E, Rallis G, Varthalitis I, Galani E, Lazaridis G, Papaxoinis G, Pectasides D, Aravantinos G, Makatsoris T, Kalogeras KT, Fountzilas G. Pentheroudakis G, et al. PLoS One. 2015 May 13;10(5):e0124612. doi: 10.1371/journal.pone.0124612. eCollection 2015. PLoS One. 2015. PMID: 25970543 Free PMC article. Clinical Trial.
611 results